FDA Greenlights Galcanezumab (Emgality) for Migraine Prevention

On the heels of recent approvals for two other calcitonin gene-related peptide (CGRP) antagonists for the prevention of migraine in adults, the FDA has approved the anti-CGRP galcanezumab.
FDA Approvals

Source link

Related posts

Introvert? You may just be bad at recognizing faces


Chemotherapy: Can It Negatively Affect Your Brain?


Futurity: Musical surprises light up the brain’s reward center


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World